Severe Ulcerative Esophagitis Induced by Crizotinib Therapy

Crizotinib is an oral tyrosine-kinase inhibitor that inhibits anaplastic lymphoma kinase (ALK) in gene-rearranged non-small cell lung cancer (NSCLC). In 2011, the Food and Drug Administration approved crizotinib for treatment of locally advanced or metastatic ALK-positive NSCLC. The crizotinib adver...

Descripción completa

Detalles Bibliográficos
Autores principales: Jalil, Ala' A Abdel, Craig, Jamie, Bajaj, Rajesh, Spurling, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435292/
https://www.ncbi.nlm.nih.gov/pubmed/26157832
http://dx.doi.org/10.14309/crj.2014.8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435292/
https://www.ncbi.nlm.nih.gov/pubmed/26157832
http://dx.doi.org/10.14309/crj.2014.8

Ejemplares similares